MOTS-c is the mitochondrial peptide in cellular energy. Encoded within mitochondrial DNA, it connects exercise-responsive human biology with administered metabolic and physical-capacity findings in mice.
The peptide that mitochondria encode
MOTS-c is the only mitochondrial-derived peptide in this comparison. It is encoded within mitochondrial 12S rRNA, detected in human muscle and circulation, and increased after cycling in a study of 10 young men. Administered mouse studies add metabolic and physical-capacity findings.
NAD+ is a coenzyme, B12 is a vitamin with a deficiency state, and glutathione belongs to redox biology. Those are useful adjacent products, but MOTS-c alone owns the mitochondrial-peptide question.
What belongs in this collection
- MOTS-c: best matched to mitochondrial signaling and metabolic-fitness research.
- NAD+ formats: best matched to a direct NAD and cellular-energy routine.
- B12: best matched to a measured or strongly suspected B12 deficiency.
- glutathione: best matched to antioxidant and redox interest.
MOTS-c is the mitochondrial peptide in this set: a 16-amino-acid molecule encoded by a short open reading frame within mitochondrial 12S rRNA and detected in human skeletal muscle and circulation. Rebody's intended format is an injection vial. NAD+, B12, and glutathione address distinct pathways through their own formats, evidence, and instructions.
How the options differ
| Option | Biological question | Practical reason to choose it | Evidence boundary |
|---|---|---|---|
| MOTS-c injection | Mitochondrial signaling and metabolic research | Closest peptide match to the query | administered human outcomes are still being studied |
| NAD+ formats | NAD-dependent cellular energy biology | Current injection, nasal, and sublingual routines | Cellular role does not establish a felt energy result |
| Methylcobalamin B12 injection | Vitamin B12 deficiency | Best choice when low B12 is measured | Deficiency evidence does not apply to B12-replete people |
| Glutathione injection | Antioxidant biology | Current choice for antioxidant intent | It should not be merchandised as another energy injection |
The routines differ across MOTS-c, NAD+, B12, and glutathione. Preparation, storage, site rotation, supplies, and sharps disposal can decide which biological choice becomes a sustainable routine.
Why MOTS-c leads this search
Among MOTS-c, NAD+ formats, B12, glutathione, MOTS-c leads because its molecule and evidence are closest to the shopper's question. The evidence is specific: In 10 young men, a stationary-bike session increased the body's own MOTS-c in skeletal muscle and serum. That was human exercise physiology, not treatment with a MOTS-c injection. Experiments that administered MOTS-c and improved physical-capacity or metabolic measures used mice. A recruiting Phase 2a trial plans 120 adults with prediabetes and overweight or obesity, 12 weeks of subcutaneous MOTS-c or placebo, and an OGTT-derived insulin-sensitivity endpoint. Results are not posted.
What the research measured
The key distinction is administration. Cycling increased the participants’ own MOTS-c in a study of 10 young men; the experiments that administered MOTS-c and improved physical-capacity or metabolic measures were performed in mice. The 120-person Phase 2a trial is recruiting and has posted no results.
Four products called “energy” that do four different jobs
MOTS-c is a mitochondrial-encoded signaling peptide. NAD+ is a coenzyme used throughout cellular metabolism. Methylcobalamin is vitamin B12, and a low B12 result can directly explain fatigue or neurologic symptoms. Glutathione sits in antioxidant and redox biology. None becomes evidence for another merely because all four appear under “cellular energy.”
That distinction changes the first move. A person with low B12 has a cause-specific answer. Someone deliberately choosing an NAD+ routine has three routes to compare. Glutathione belongs to antioxidant intent. MOTS-c is the most direct mitochondrial-peptide research match; administered-human efficacy results are not established.
Start with the energy problem, not the molecule
“Low energy” can mean sleepiness, reduced exercise tolerance, muscle weakness, a post-meal crash, cognitive slowing, or loss of motivation. Those patterns point to different questions. Sleep duration, iron status, thyroid function, B12, medication effects, calorie intake, infection, mood, cardiovascular symptoms, and glucose regulation can matter more than a peptide category.
A useful baseline names the failure precisely: afternoon sleepiness, fewer watts on the bike, slower walking pace, inability to finish a usual set, or a laboratory abnormality. A vague energy score makes every intervention look plausible and none of them interpretable.
What is available now
The MOTS-c guide keeps vial, concentration, schedule, supply, storage, and price together. Adjacent options include NAD+ injection, nasal spray, and sublingual tablets; methylcobalamin B12 injection; and glutathione injection.
Current Rebody prices lead with the actual first charge: B12 is $44.50 first month, then $89/month; glutathione is $74.50 first month, then $149/month. NAD+ price depends on route: injection is $223.50 for the first two-month shipment, then $298 every two months ($149/month equivalent); the current Rebody nasal-spray package is 12 mL at $59.50 first month, then $119/month; sublingual tablets are $99.50 first month, then $199/month.
How to judge a cellular-energy claim
Look for five labels: the exact molecule, whether it was administered or merely measured in the body, the species or population, the route, and the endpoint. In the human cycling study, exercise increased endogenous MOTS-c in muscle and serum. In mouse experiments, administered MOTS-c changed metabolic and capacity measures. The recruiting Phase 2a trial is the first substantial administered-human test, and it has no posted result.
An ATP diagram, AMPK explanation, or mitochondrial animation is mechanism, not proof that fatigue improves. A review can describe pump comfort or shipping; it cannot establish mitochondrial function.
A useful result has to survive an ordinary week
“Cellular energy” is too vague to track by itself. Pick one human outcome before choosing a product: the 3 p.m. crash, the amount of work completed before fatigue, repeated training power, or the ability to get through a normal day without another coffee. Record it under comparable conditions for two weeks. Sleep duration, meal timing, illness, training load, and caffeine can move every one of those measures more than a supplement or prescription.
Then match the observation to the biology. Numbness, balance changes, anemia, restrictive eating, or metformin use can make the B12 question more important. A direct interest in NAD biology is a different decision. Oxidative-stress language points toward glutathione, but it still does not establish fatigue relief. MOTS-c belongs to mitochondrial signaling research and remains unavailable from Rebody.
This discipline prevents a common error: treating a better-feeling afternoon as proof that mitochondria produced more ATP. Symptoms matter, but they do not identify a molecular mechanism on their own. A useful trial has one target, a stable baseline, and a stopping rule when the target does not move.
Questions about mitochondrial peptides and energy
Is MOTS-c the same thing as NAD+?
No. MOTS-c is a 16-amino-acid mitochondrial-derived signaling peptide. NAD+ is a coenzyme. Their biology, routes, evidence, and product facts are separate.
Which option makes the most sense when B12 is low?
B12. A documented deficiency gives methylcobalamin the clearest cause-to-treatment logic in this group. That does not make B12 a universal energy injection.
Does glutathione increase energy?
Glutathione belongs to antioxidant and redox biology. The current evidence cited here does not establish it as an endurance, cognition, or mitochondrial-peptide treatment.
Can MOTS-c improve cellular energy in people?
That is not established. Human research has measured the body’s own MOTS-c response to exercise. Administered benefit findings came from mice; the 12-week human Phase 2a trial is recruiting.
Is MOTS-c allowed in tested sport?
No. MOTS-c is prohibited under the 2026 World Anti-Doping Agency list. Competitive athletes should not treat a peptide guide or “wellness” framing as an antidoping exemption.
MOTS-c owns mitochondrial energy research
Choose MOTS-c when the goal is a peptide rooted in mitochondrial signaling, metabolic fitness, and physical capacity. Choose NAD+, B12, or glutathione when the goal changes to direct coenzyme use, measured deficiency, or antioxidant biology. No adjacent product duplicates what MOTS-c is.
Keep reading
- Cellular-Energy Injections: MOTS-C, NAD+, B12, and Glutathione
- Mitochondrial Health Peptides for Healthy Aging
- MOTS-C vs NAD+ vs B12: Which One Matches Your Energy Problem?